In line with its apparent role in DNA damage repair, high ACLY expression predicted worse outcome only in patients that received RT, but not in patients that did not, thus indicating that ACLY is a predictive biomarker for RT success, of which there is a critical need in HNSCC. The gene discussed is ACLY; the disease is head and neck squamous cell carcinoma.